SIR-Spheres® Microspheres Versus Transarterial Chemoembolisation in Patients With Unresectable Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This study is open to patients with primary HCC who cannot be treated by potentially curative
treatment modalities, such as surgical resection, liver transplantation or percutaneous
ablation.
Patients that satisfy the study eligibility criteria will be randomised in a 1: 1 ratio to
receive either Radioembolisation with SIR-Spheres Microspheres or the standardised
Transarterial Chemoembolisation procedure.
Study Objectives
This study will evaluate and compare quality of life as well as safety and efficacy of RE or
TACE in patients with unresectable HCC. Patients will be followed for a minimum of 12 months
or until death wherever possible in the evaluation of the primary and secondary objectives of
this study.